Safety scrutiny around biologic drugs is widening after a signal in FDA records points to hair loss as a potential adverse effect category under closer monitoring. The report frames the observation in the context of biologics’ expanding global use for immune-mediated conditions such as psoriasis and atopic dermatitis. The development is important for pharmacovigilance and for patient counseling, because cosmetic and quality-of-life adverse events can influence adherence and treatment continuation. For biotech and clinical teams, the next step is typically confirmation through systematic review of labeling, case series, and any mechanistic hypotheses that connect immune modulation to hair follicle cycling.